Patient factors associated with the use of biologic DMARD among children without systemic arthritis (n = 2502).
| Patient Factor | Univariate OR (95% CI) | Multivariable OR (95% CI) |
|---|---|---|
| Extended oligoarthritis* | 3.5 (2.6–4.8) | — |
| RF– polyarthritis* | 4.7 (3.8–5.9) | 1.9 (1.5–2.5) |
| RF+ polyarthritis* | 8.6 (6.1–12) | 3.4 (2.2–5.2) |
| Psoriatic arthritis* | 5.7 (4.0–8.1) | 2.7 (1.8–3.9) |
| ERA* | 3.5 (2.6–4.7) | — |
| History ≥ 5 joints | 3.7 (3.1–4.4) | 2.3 (1.8–2.9) |
| HLA-B27 | 1.3 (1.0–1.8) | — |
| Uveitis | 1.8 (1.4–2.3) | 2.3 (1.7–3.0) |
| IBD | 3.3 (1.8–6.0) | 3.0 (1.4–2.6) |
| Sacroiliac tenderness | 1.9 (1.4–2.4) | 1.7 (1.2–2.4) |
| Enthesitis | 1.6 (1.3–2.1) | 1.9 (1.4–2.6) |
| Psoriasis rash | 2.0 (1.4–2.8) | — |
| ACPA | 3.4 (2.3–5.2) | 1.9 (1.1–3.2) |
| Radiographic damage | 3.0 (2.5–3.7) | 2.2 (1.7–2.8) |
| Disease duration, yrs | 1.1 (1.1–1.2) | 1.1 (1.1–1.1) |
↵* Compared to oligoarthritis category. DMARD: disease-modifying antirheumatic drug; RF: rheumatoid factor; ERA: enthesitis-related arthritis; IBD: inflammatory bowel disease; ACPA: anticitrullinated protein antibodies.